Selection of anticoagulants for leukocytapheresis therapy in cases of active ulcerative colitis

Blood Purification

Volumn 25, Issue 4, 2007, Pages 370-376

  Kanke, Kazunari ^a   Hoshino, Mina ^a   Tominaga, Keiichi ^a   Nakano, Michiko ^a   Terano, Akira ^a   Hiraishi, Hideyuki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Anticoagulant; Cellsorba EX; Heparin; Leukocytapheresis; Ulcerative colitis

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT MESILATE;

ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTAPHERESIS; DEVICE; DRUG SAFETY; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERTENSION; HYPOTENSION; LEUKOCYTAPHERESIS THERAPY; LEUKOCYTE; PRIORITY JOURNAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; ULCERATIVE COLITIS;

ANTICOAGULANTS; BIOCOMPATIBLE MATERIALS; BIOLOGICAL MARKERS; BRADYKININ; COLITIS, ULCERATIVE; CROSS-OVER STUDIES; FILTRATION; FLUSHING; GUANIDINES; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYPOTENSION; LEUKAPHERESIS; LEUKOCYTE REDUCTION PROCEDURES; NAUSEA; POLYESTERS; URETHANE;

EID: 34548845093     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107712     Document Type: Article

References (26)

1. Sawada K, Ohnishi K, Fukui S, Yamada K, Yamamura M, Amano K, Amano K, Wada M, Tanida N, Satomi M, et al: Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol 1995;30:322-329.
2. Shirokaze J: Leukocytapheresis using a leukocyte removal filter. Ther Apher 2002;6:261-266.
3. Yamaji K, Yang K, Tsuda H, Hashimoto H: Fluctuations in the peripheral blood leukocyte and platelet counts in leukocytapheresis in healthy volunteers. Ther Apher 2002;6:402-412.
4. Sawada K, Muto T, Shimoyama T, Satomi M, Sawada T, Nagawa H, Hiwatashi N, Asakura H, Hibi T: Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 2003;9:307-321.
5. Hild M, Söderström T, Egberg N, Lundahl J: Kinetics of bradykinin levels during and after leukocyte filtration of platelet concentrates. Vox Sang 1998;75:18-25.
6. Kojima S, Shiba M, Kuramochi M, Yamamoto A: Effect of nafamostat mesilate on bradykinin generation and hemodynamics during LDL apheresis. Artif Organs 1995;19:135-139.
7. Shimizu M, Tsuda H, Sanaka T, Ide K: Present status of therapeutic apheresis in Japan: survey report. (Survey Subcommittee, Scientific Committee, Japanese Society for Apheresis). Ther Apher 1998;2:172-181.
8. Norda R, Berseus O, Stegmayr B: Adverse events and problems in therapeutic hemapheresis. A report from the Swedish registry. Transfus Apher Sci 2001;25:33-41.
9. Yamazato M, Mano R, Oshiro-Chinen S, Tomiyama N, Sakima A, Ishida A, Tana T, Tozawa M, Muratani H, Iseki K, Takishita S: Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient. Intern Med 2002;41:864-866.
10. Higuchi N, Yamazaki H, Kikuchi H, Gejyo F: Anaphylactoid reaction induced by a protease inhibitor, nafamostat mesilate, following nine administrations in a hemodialysis patient. Nephron 2000;86:400-401.
11. Andoh A, Ogawa A, Kitamura K, Inatomi O, Fujino S, Tsujikawa T, Sasaki M, Mitsuyama K, Fujiyama Y: Suppression of interleukin-1beta- and tumor necrosis factor-alpha-induced inflammatory responses by leukocytapheresis therapy in patients with ulcerative colitis. J Gastroenterol 2004;39:1150-1157.
12. Noguchi M, Hiwatashi N, Hayakawa T, Toyota T: Leukocyte removal filter-passed lymphocytes produce large amounts of interleukin-4 in immunotherapy for inflammatory bowel disease: role of bystander suppression. Ther Apher 1998;2:109-114.
13. Hanai H, Takeuchi K, Iida T, et al: Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-1538.
14. Sawada K, Kusugami K, Suzuki Y, Bamba T, Munakata A, Hibi T, Shimoyama T: Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective casecontrol study with sham apheresis as placebo treatment. Am J Gastroenterol 2005;100:1362-1369.
15. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR: Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001;16:1-9.
16. Kanke K, Nakano M, Hiraishi H, Terano A: Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis 2004;36:799-802.
17. Hanai H, Watanabe F, Yamada M, et al: Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion 2004;70:36-44.
18. Kawasaki Y, Suzuki J, Suzuki S, Suzuki H: Leukocytapheresis with leukocyte removal filter for severe ulcerative colitis in childhood. J Pediatr Gastroenterol Nutr 2004;39:422-425.
19. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostermg H, Seidel D, Scheler F: Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int 1988;33:890-896.
20. Olbricht CJ, Schaumann D, Fischer D: Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors. Lancet 1992;34:908-909.
21. Verresen L, Waer M, Vanrenterghem Y, Michielsen P: Angiotensin- converting-enzyme inhibitors and anaphylactoid reactions to high-flux membrane dialysis. Lancet 1990;336:1360-1362.
22. Kojima S, Ogi M, Yoshitomi Y, Kuramochi M, Ikeda J, Naganawa M, Hatakeyama H: Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis. Int J Artif Organs 1997;20:178-183.
23. Fujii S, Hitomi Y: New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981;661:342-345.
24. Klein B, Faridi A, von Tempelhoff GF, Heilmann L, Mittermayer C, Rath W: A whole blood flow cytometric determination of platelet activation by unfractionated and low molecular weight heparin in vitro. Thromb Res 2002;108:291-296.
25. Stead N, Kaplan AP, Rosenberg RD: Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem 1976;251:6481-6488.
26. Rachmilewitz D: Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized trial. BMJ 1989;298:82-86.